

HEXIMA LIMITED

ASX ANNOUNCEMENT



5 November 2021

NOTICE UNDER SECTION 708A(5)(e) OF THE *CORPORATIONS ACT 2001* (CTH)

This notice is given by Hexima Limited ACN 079 319 314 (ASX: HXL) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company has today issued 19,600,000 fully paid ordinary shares (**New Shares**) at an issue price of \$0.32 per New Share to a number of sophisticated and institutional investors pursuant to the first tranche of the placement announced to ASX on 1 November 2021. The New Shares rank equally with the existing shares on issue.

The Company advises that:

1. the New Shares were issued without disclosure under part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. section 674 and 674A of the Corporations Act; and
3. as at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

This announcement is authorised for release to ASX by the Board of Directors of Hexima Limited.

Enquiries:

Dr Nicole van der Weerden
Chief Operating Officer
n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please [click here](#)

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on [Twitter](#) and [LinkedIn](#) or email us at info@hexima.com.au.